You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)
SBC: NANOVALENT PHARMACEUTICALS INC Topic: 102Project Summary The goal of this Fast Track STTR project is to determine proof-of-principle and efficacy of a novel blood brain barrier (BBB) penetrating therapeutic nanoparticle for the potential treatment of otherwise intractable brain tumors like glioblastoma multiforme (GBM). This project seeks to demonstrate that novel, targetable nanoparticles can delivery therapeutic substances to human bra ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A micronized electrostatic precipitator for next-generation respiratory protection against pathogenic aerosols
SBC: HENLEY ION, LLC Topic: NIAIDPROJECT SUMMARY Many pathogens, such as severe acute respiratory coronavirus 2 (SARS-CoV-2) and Mycobacterium tuberculosis, spread via aerosol transmission and inflict global public health and economic consequences. SARS-CoV-2 has infected over 450 million people, led to over 6 million fatalities, and caused major economic losses. The tuberculosis-causing bacterium and longstanding global health e ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Booth™ by Opio™: Developing technology to expand the reach of opioid treatment programs into rural and underserved areas.
SBC: Opio Connect, Inc. Topic: NIDAThe goal of this project is to develop a treatment booth with technology that allows opioid treatment programs to remotely dispense, either methadone or buprenorphine, under medical observation through telemedicine to a patient in a treatment booth. We believe that robotic automation is the ideal application to perform the same mechanical functions of the nurse at the dosing window. Specifically, ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel non-narcotic analgesic for acute and chronic pain
SBC: South Rampart Pharma, LLC Topic: 106PROJECT SUMMARYSouth Rampart Pharma (SRP) is an early clinical-stage company focused on developing SRP-001, a novel non-opioid designed to treat moderate-to-severe acute and chronic pain without the dose-limiting hepatotoxicity of acetaminophen and nephrotoxicity of NSAIDs, and the misuse and addictive potential of opioids. SRP-001 is currently in Phase 1 trials where interim data support the expe ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options
SBC: Golden Helix, Inc. Topic: 172Abstract Pharmacogenomics, the study of how an individual's genetic makeup affects their response to drugs, has undergone rapid advancements. This has occurred alongside a decrease in the cost of genotyping technology, making implementation of pharmacogenomics into clinical practice increasingly feasible. Personalized medicine leveraging pharmacogenomics is gaining momentum to optimize drug choice ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne.
SBC: DERMAXON LLC Topic: NIAMSProject Summary / Abstract DermaXon's project goal is to develop efficacious, substrate-based, selective inhibitors of CYP26s, the enzymes responsible for the metabolism of all-trans retinoic acid (atRA) in the epidermis, as an oral treatment for severe recalcitrant acne. This approach will provide an improved acne therapeutic without the adverse effects associated with currently marketed retinoid ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Silent Mobility Vehicle Cooling for HMMWV
SBC: BASCOM HUNTER TECHNOLOGIES INC Topic: A224006Redacted.
SBIR Phase II 2023 Department of DefenseArmy -
Implementation and validation of a lung x-ray interferometry imaging system, with applications to COPD, COVID-19 and other lung diseases
SBC: REFINED IMAGING, LLC Topic: NHLBIAbstractLung diseases ranging from cancer to chronic obstructive pulmonary disease (COPD) affect large numbers of men and women worldwide each year. Current news reports describe the respiratory impact of COVID-19; likewise, the past year has seen extensive coverage of the respiratory problems caused by vaping. Worldwide, lung diseases of all types result in millions of deaths per year at a stagge ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease
SBC: Oleolive, Inc. Topic: NIASUMMARY Alzheimer’s disease (AD) and related dementias are devastating conditions that affect millions of people, but no effective treatment options exist. Studies are currently being performed as part of the funded Phase II STTR parent award to test efficacy of a potential AD therapeutic, OL-003, in two additional animal models and assess pharmacology and toxicology. The overarching goal of the ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Chemosensitization of Glioblastoma by Propentofylline
SBC: Oleolive, Inc. Topic: 102SUMMARY Glioblastoma (GBM) is the most common primary tumor of the CNS with limited treatment options and a poor clinical prognosis. Standard of care treatment, including surgical resection, radiation therapy and concurrent temozolomide (TMZ) treatment followed by adjuvant TMZ, produces a median survival in newly diagnosed GBM of ~15 months. Tumor recurrence happens due to therapy resistant tumor ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health